Rynazal, Ryza http://orcid.org/0000-0003-4968-4346
Fujisawa, Kota
Shiroma, Hirotsugu
Salim, Felix
Mizutani, Sayaka
Shiba, Satoshi
Yachida, Shinichi
Yamada, Takuji
Funding for this research was provided by:
JST AIP Acceleration Research (JPMJCR19U3)
the Japan Society for the Promotion of Science (KAKENHI 16H06279 (PAGS))
Japan Agency for Medical Research and Development (21ck0106546h0002; 21cm0106477h0002, JP20jk0210009)
National Cancer Center Research and Development Fund (2020-A-7)
Japan Health Research Promotion Bureau (JH2022-B-01)
Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University
Joint Research Project of the Institute Medical Science, the University of Tokyo
Takeda Science Foundation
Mitsubishi Foundation
Princess Takamatsu Cancer Research Fund
Yasuda Medical Foundation
Article History
Received: 30 April 2022
Accepted: 17 January 2023
First Online: 9 February 2023
Declarations
:
: The bacterial relative abundance data and clinical information used in this study were obtained from Yachida et al. [CitationRef removed]. They obtained the samples under conditions of informed consent and with approval of the institutional review boards of the participating institutes (National Cancer Center, 2013-244; Tokyo Institute of Technology, 2014018).
: T.Y. is a founder of Metagen Inc., Metagen Therapeutics Inc., and digzyme Inc. Metagen Inc. focuses on the design and control of the gut environment for human health. Metagen Therapeutics Inc. focuses on drug discovery and development which utilizes microbiome science. All of the companies had no control over the interpretation, writing, or publication of this work. The terms of these arrangements are being managed by the Tokyo Institute of Technology in accordance with its conflict of interest policies.